DK2463297T3 - Oxygen Compositions and Methods - Google Patents

Oxygen Compositions and Methods Download PDF

Info

Publication number
DK2463297T3
DK2463297T3 DK11189814.4T DK11189814T DK2463297T3 DK 2463297 T3 DK2463297 T3 DK 2463297T3 DK 11189814 T DK11189814 T DK 11189814T DK 2463297 T3 DK2463297 T3 DK 2463297T3
Authority
DK
Denmark
Prior art keywords
nox
leu
glu
val
gly
Prior art date
Application number
DK11189814.4T
Other languages
Danish (da)
English (en)
Inventor
Stephen P L Cary
Elizabeth M Boon
Emily Weinert
Michael A Marletta
Jonathan A Winger
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK2463297T3 publication Critical patent/DK2463297T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499Blood gas standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK11189814.4T 2006-05-22 2007-05-21 Oxygen Compositions and Methods DK2463297T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150506P 2006-05-22 2006-05-22
EP07795174A EP2032156B1 (en) 2006-05-22 2007-05-21 Compositions and methods for the delivery of oxygen

Publications (1)

Publication Number Publication Date
DK2463297T3 true DK2463297T3 (en) 2017-01-09

Family

ID=38779160

Family Applications (4)

Application Number Title Priority Date Filing Date
DK07795174.7T DK2032156T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af oxygen
DK11189807.8T DK2463294T3 (en) 2006-05-22 2007-05-21 Compositions and Methods for Delivery of Nitric Oxide
DK07795153.1T DK2040740T3 (en) 2006-05-22 2007-05-21 COMPOSITIONS AND PROCEDURES FOR DELIVERING NITROGEN MONOXIDE
DK11189814.4T DK2463297T3 (en) 2006-05-22 2007-05-21 Oxygen Compositions and Methods

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK07795174.7T DK2032156T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af oxygen
DK11189807.8T DK2463294T3 (en) 2006-05-22 2007-05-21 Compositions and Methods for Delivery of Nitric Oxide
DK07795153.1T DK2040740T3 (en) 2006-05-22 2007-05-21 COMPOSITIONS AND PROCEDURES FOR DELIVERING NITROGEN MONOXIDE

Country Status (12)

Country Link
US (7) US8404632B2 (enExample)
EP (7) EP2463294B1 (enExample)
JP (5) JP5698906B2 (enExample)
CN (5) CN104689300B (enExample)
AU (2) AU2007268052B2 (enExample)
BR (2) BRPI0711901A2 (enExample)
CA (2) CA2653080C (enExample)
DK (4) DK2032156T3 (enExample)
ES (4) ES2399662T3 (enExample)
IN (2) IN2013MN00601A (enExample)
NZ (4) NZ594457A (enExample)
WO (2) WO2007139791A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463294B1 (en) 2006-05-22 2016-10-19 The Regents of The University of California Compositions and methods for the delivery of nitric oxide
US20110243849A1 (en) * 2010-04-02 2011-10-06 Marletta Michael A Heme-binding photoactive polypeptides and methods of use thereof
EP3922643A1 (en) 2013-01-07 2021-12-15 Omniox, Inc. Polymeric forms of h-nox proteins
SG10201908269SA (en) * 2015-03-17 2019-10-30 Omniox Inc Modulation of tumor immunity by protein-mediated o2 delivery
BR112018016829A2 (pt) * 2016-02-16 2018-12-26 Omniox Inc método para tratar acidente vascular cerebral em um indivíduo, método para administrar oxigênio a um indivíduo, método para tratar um ataque isquêmico transitório em um indivíduo, método para tratar uma lesão cerebral hipóxica em um indivíduo, composição, composição farmacêutica, uso de uma composição, kit e método para preparar uma composição
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス, インコーポレイテッド H−noxタンパク質の重合体形態
WO2020037052A1 (en) 2018-08-15 2020-02-20 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
KR102776925B1 (ko) 2019-06-25 2025-03-11 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
CA3153501A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
PH12022551441A1 (en) 2019-12-24 2023-11-20 Carna Biosciences Inc Diacylglycerol kinase modulating compounds
CR20220396A (es) 2020-02-14 2022-11-14 Jounce Therapeutics Inc Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
US20240043427A1 (en) 2020-05-01 2024-02-08 Gilead Sciences, Inc. Cd73 compounds
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
ES2999273T3 (en) 2022-03-17 2025-02-25 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Parp7抑制劑
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
AU6766994A (en) 1994-04-01 1995-10-23 Unisyn Technologies, Inc. Culture media additives for hollow fiber bioreactors
JP4583510B2 (ja) * 1997-02-28 2010-11-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 無細胞系による酸素輸送の最適化のための方法と組成物
WO1998050430A2 (en) 1997-05-02 1998-11-12 Somatogen, Inc. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6773613B1 (en) * 1998-10-15 2004-08-10 Sangart, Inc. Method for production of stroma-free hemoglobin
ATE553782T1 (de) * 1999-12-22 2012-05-15 Scripps Research Inst Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung
CA2410953A1 (en) * 2000-06-29 2002-01-10 Incyte Genomics, Inc. Adenylyl and guanylyl cyclases
US20030096240A1 (en) * 2000-09-19 2003-05-22 Ferid Murad Genomic organization of mouse and human sGC
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP4873860B2 (ja) * 2002-08-30 2012-02-08 バイオレクシス ファーマシューティカル コーポレーション 改変トランスフェリン融合タンパク質
CN1660100A (zh) * 2002-12-09 2005-08-31 上海倍艺医药科技有限公司 一种治疗糖尿病及其并发症的药物
EP2463294B1 (en) 2006-05-22 2016-10-19 The Regents of The University of California Compositions and methods for the delivery of nitric oxide

Also Published As

Publication number Publication date
BRPI0711901A2 (pt) 2012-03-06
ES2611157T3 (es) 2017-05-05
CN101495134A (zh) 2009-07-29
DK2032156T3 (da) 2013-02-18
NZ573004A (en) 2012-06-29
CA2653080A1 (en) 2007-12-06
CN101495506A (zh) 2009-07-29
WO2007139791A2 (en) 2007-12-06
EP2040740A2 (en) 2009-04-01
EP2032156A2 (en) 2009-03-11
DK2040740T3 (en) 2014-12-01
US20130289252A1 (en) 2013-10-31
JP2014224156A (ja) 2014-12-04
IN2013MN00601A (enExample) 2015-06-12
EP2032156B1 (en) 2012-11-21
CN101495134B (zh) 2016-08-03
EP2474554A3 (en) 2012-10-03
JP6118772B2 (ja) 2017-04-19
US9493526B2 (en) 2016-11-15
EP2040740A4 (en) 2009-10-21
EP2463294B1 (en) 2016-10-19
JP2015007108A (ja) 2015-01-15
ES2610653T3 (es) 2017-04-28
EP2463297A1 (en) 2012-06-13
JP2009538133A (ja) 2009-11-05
CA2653101C (en) 2016-12-13
JP2017137337A (ja) 2017-08-10
EP2463295A1 (en) 2012-06-13
JP5698906B2 (ja) 2015-04-08
US8404631B2 (en) 2013-03-26
AU2007268028A1 (en) 2007-12-06
HK1129688A1 (en) 2009-12-04
EP2463296A1 (en) 2012-06-13
CA2653101A1 (en) 2007-12-06
BRPI0711767B1 (pt) 2018-05-15
US8404632B2 (en) 2013-03-26
AU2007268052B2 (en) 2013-07-04
US20100266673A1 (en) 2010-10-21
NZ573003A (en) 2012-06-29
CN106075388A (zh) 2016-11-09
WO2007139767A3 (en) 2008-02-07
EP2474554A2 (en) 2012-07-11
CN101495506B (zh) 2016-08-10
JP5698905B2 (ja) 2015-04-08
CN108273040A (zh) 2018-07-13
EP2032156A4 (en) 2009-11-11
US20170267732A1 (en) 2017-09-21
US10202428B2 (en) 2019-02-12
WO2007139767A2 (en) 2007-12-06
US20150266931A1 (en) 2015-09-24
US20100285104A1 (en) 2010-11-11
JP2009538134A (ja) 2009-11-05
NZ594457A (en) 2013-06-28
CN104689300B (zh) 2018-06-05
DK2463294T3 (en) 2017-01-16
AU2007268028B2 (en) 2013-03-14
US9493527B2 (en) 2016-11-15
CA2653080C (en) 2019-02-12
EP2463294A1 (en) 2012-06-13
ES2399662T3 (es) 2013-04-02
CN104689300A (zh) 2015-06-10
IN2013MN00600A (enExample) 2015-06-12
JP6458070B2 (ja) 2019-01-23
BRPI0711767A2 (pt) 2012-01-10
NZ594456A (en) 2013-06-28
BRPI0711767B8 (pt) 2021-05-25
JP6118296B2 (ja) 2017-04-19
EP2463297B1 (en) 2016-10-19
WO2007139791A3 (en) 2008-05-02
EP2040740B1 (en) 2014-09-03
US20150376250A1 (en) 2015-12-31
AU2007268052A1 (en) 2007-12-06
ES2525226T3 (es) 2014-12-19
CN106075388B (zh) 2021-06-29
US20130288970A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
DK2463297T3 (en) Oxygen Compositions and Methods
AU2013201117B2 (en) Compositions and Methods for the Delivery of Oxygen
AU2013201114B2 (en) Compositions and Methods for the Delivery of Nitric Oxide
HK1129688B (en) Compositions and methods for the delivery of oxygen
HK1172913A (en) Compositions and methods for the delivery of oxygen
HK1172037A (en) Compositions and methods for the delivery of oxygen
HK1130265A (en) Compositions and methods for the delivery of nitric oxide
HK1130265B (en) Compositions and methods for the delivery of nitric oxide